Ranke M, Weber B, Bierich J R
Eur J Pediatr. 1979;132(4):221-38. doi: 10.1007/BF00496846.
The results of long term treatment with human growth hormone (Crescormon, 12.4 IU/m2/week) in 36 patients with idiopathic growth hormone deficiency are given. Birth trauma--in particular assisted breech delivery (30%)--is the major aetiological cause. Twelve patients had isolated growth hormone deficiency (IGHD), 24 had multiple pituitary hormone deficiencies (MPHD) of which 19 were treated with additional thyroid hormones. The results were judged by the criteria of height velocity, total height gain and change of height prediction (TW2, age based). It is concluded that the growth hormone dose chosen in many cases is insufficient to maintain high growth rates after the first year of treatment, when "catch-up" no loner takes place. The tendency of patients supplemented with thyroid hormone to grow better--without additional bone-age advancement--calls for careful search for hypothyroidism and suggests the use of thyroxin in cases of doubt.
本文给出了36例特发性生长激素缺乏症患者接受人生长激素(克瑞思萌,12.4 IU/m²/周)长期治疗的结果。出生时的创伤——尤其是臀位助产(30%)——是主要病因。12例患者为孤立性生长激素缺乏症(IGHD),24例有多垂体激素缺乏症(MPHD),其中19例接受了额外的甲状腺激素治疗。结果根据身高增长速度、总身高增加量和身高预测值变化(TW2,基于年龄)的标准进行判断。得出的结论是,在许多情况下,所选择的生长激素剂量不足以在治疗第一年之后维持高生长速度,此时“追赶生长”不再发生。补充甲状腺激素的患者生长较好的趋势——无额外的骨龄进展——需要仔细筛查甲状腺功能减退症,并建议在有疑问的情况下使用甲状腺素。